Jump to content

Antengene Announces its U.S. Partner, Karyopharm Therapeutics Inc., has received FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy


In The News

Recommended Posts

Archived

This topic is now archived and is closed to further replies.



×
×
  • Create New...